The KEYNOTE-062 phase III trial randomized patients to pembrolizumab alone, pembrolizumab and chemotherapy (5-FU and oxaliplatin), and chemotherapy alone in patients with advanced GC and PD-L1 CPS ≥ 1. Here, CD274 is linked to gastric cancer.